{"name":"Ace Cells Lab Limited","slug":"ace-cells-lab-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ACE Reno","genericName":"ACE Reno","slug":"ace-reno","indication":"Hypertension","status":"marketed"}]}],"pipeline":[{"name":"ACE Reno","genericName":"ACE Reno","slug":"ace-reno","phase":"marketed","mechanism":"ACE Reno is an angiotensin-converting enzyme (ACE) inhibitor that works by relaxing blood vessels and reducing blood pressure.","indications":["Hypertension","Heart failure"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxPQlUzMndrMmp6QVE2RUo4RFZNMlBjWERBVWRHUVNPUm1tQlFCQlVPS0IxTG0wb08zcDJGVThEeWd5RU1qOVhlRmFUS3o5NnA0QVdhMl95Y3dMX0hodkxfTUdRelBDdFFnalhHWHFkTjB0MWVBZW1xLXI5TlRUWWxhOG00dEZnV25lV3U2Vml1WDNuRnlZeC1VWk9SekxXdFRiOGJTQ3ZINHZwVTY3QnJBcEY1bE5oM3hFNW1ucFpWSWlMNDRiQmpxc094SGRYbXlfem95OWpYMUwxWFZnMlpyTVZ3QnZwbEZwX2pTZllCQTBmOWhyOUFVaE9pekVvZlYyazlIMDJMVGZ6LWpyM1R4WlcyZXltWUhHRXc?oc=5","date":"2023-01-23","type":"pipeline","source":"Cureus","summary":"Degenerative Disorder of the Temporomandibular Joint Treated With Autologous Bone Marrow-Derived Stem Cells Using the Regentime Technique: A Case Report - Cureus","headline":"Degenerative Disorder of the Temporomandibular Joint Treated With Autologous Bone Marrow-Derived Stem Cells Using the Re","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}